Cyclerion Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 6.95 million compared to USD 12.98 million a year ago. Basic loss per share from continuing operations was USD 3.2 compared to USD 6 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.93 USD | -3.62% | -16.29% | -12.54% |
Mar. 05 | Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Cyclerion Therapeutics, Inc. Appoints Regina Graul as President | CI |
1st Jan change | Capi. | |
---|---|---|
-12.54% | 7.44M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CYCN Stock
- News Cyclerion Therapeutics, Inc.
- Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023